Heterogeneity in aripiprazole diffusion for bipolar disorder treatment in the veterans health administration

Psychiatric Services

Volumn 63, Issue 12, 2012, Pages 1178-1185

  Penfold, Robert B ^a,b   Kilbourne, Amy M ^c,d   Mohr, David C ^c,e   Lai, Zongshan ^c,d   Seibert, Marjorie Nealon ^c   Bauer, Mark S ^c,f  

^a GROUP HEALTH RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e BOSTON UNIVERSITY   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; PIPERAZINE DERIVATIVE; QUINOLONE DERIVATIVE;

ADULT; ARTICLE; BEHAVIOR MODIFICATION; BIPOLAR DISORDER; BIPOLAR MANIA; DRUG APPROVAL; DRUG DIFFUSION; DRUG UPTAKE; DRUG USE; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; SUBSTANCE ABUSE; TIME SERIES ANALYSIS; UNITED STATES; VETERANS HEALTH; AGED; CROSS-SECTIONAL STUDY; GOVERNMENT; MASS COMMUNICATION; MIDDLE AGED; REGISTER; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; CROSS-SECTIONAL STUDIES; DIFFUSION OF INNOVATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; QUINOLONES; REGISTRIES; UNITED STATES; UNITED STATES DEPARTMENT OF VETERANS AFFAIRS; UNITED STATES FOOD AND DRUG ADMINISTRATION;

MLCS; MLOWN;

EID: 84878698285     PISSN: 10752730     EISSN: 15579700     Source Type: Journal    
DOI: 10.1176/appi.ps.201200061     Document Type: Article

References (57)

1. Pillarella J, Higashi A, Alexander GC, et al: Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009. Psychiatric Services 63:83-86, 2012
2. Soumerai SB: Benefits and risks of increasing restrictions on access to costly drugs in Medicaid. Health Affairs 23(1): 135-146, 2004
3. Soumerai SB, Zhang F, Ross-Degnan D, et al: Use of atypical antipsychotic drugs for schizophrenia in Maine Medicaid following a policy change. Health Affairs 27: w185-w195, 2008
4. Lu CY, Soumerai SB, Ross-Degnan D, et al: Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness. Medical Care 48:4-9, 2010
5. Valenstein M, Copeland L, Owen R, et al: Delays in adopting evidence-based dosages of conventional antipsychotics. Psychiatric Services 52:1242-1244, 2001
6. Rogers E: Diffusion of Innovations, 5th ed. New York, Free Press, 2003
7. Fung CH, Woods JN, Asch SM, et al: Variation in implementation and use of computerized clinical reminders in an integrated healthcare system. American Journal of Managed Care 10:878-885, 2004
8. Byrne JM, Elliott S, Firek A: Initial experience with patient-clinician secure messaging at a VA medical center. Journal of the American Medical Informatics Association 16:267-270, 2009
9. Cook JM, Schnurr PP, Biyanova T, et al: Apples don't fall far from the tree: influences on psychotherapists' adoption and sustained use of new therapies. Psychiatric Services 60:671-676, 2009
10. McCarthy JF, Valenstein M, Dixon L, et al: Initiation of assertive community treatment among veterans with serious mental illness: client and program factors. Psychiatric Services 60:196-201, 2009
11. Lai LL, Tan MH, Lai YC: Prevalence and factors associated with off-label antidepressant prescriptions for insomnia. Journal of Drug, Healthcare and Patient Safety 3:27-36, 2011
12. Crystal S, Olfson M, Huang C, et al: Broadened use of atypical antipsychotics: safety, effectiveness, and policy challenges. Health Affairs 28:w770-w781, 2009
13. Penfold RB, Wang W, Pajer K, et al: Spatiotemporal clusters of new psychotropic medications among Michigan children insured by Medicaid. Pharmacoepidemiology and Drug Safety 18:531-539, 2009
14. Penfold RB, Kelleher KJ, Wang W, et al: Pediatric uptake of a newly available antipsychotic medication. Pediatrics 125: 475-482, 2010
15. Alexander GC, Gallagher SA, Mascola A, et al: Increasing off-label use of antipsychotic medications in the United States, 1995-2008. Pharmacoepidemiology and Drug Safety 20:177-184, 2011
16. Maher AR, Maglione M, Bagley S, et al: Efficacy and comparative effectiveness of atypical antipsychotic medications for offlabel uses in adults: A systematic review and meta-analysis. JAMA 306:1359-1369, 2011
17. Valente TW, Davis RL: Accelerating the diffusion of innovations using opinion leaders. Annals of the American Academy of Political and Social Science 566:55-67, 1999
18. Valente TW, Pumpuang P: Identifying opinion leaders to promote behavior change. Health Education and Behavior 34:881-896, 2007
19. Steinman MA, Harper GM, Chren MM, et al: Characteristics and impact of drug detailing for gabapentin. PLoS Medicine 4: e134, 2007
20. Kmietowicz Z: Eli Lilly pays record $1.4bn for promoting off-label use of olanzapine. BMJ 338:b217, 2009
21. Spielmans GI: The promotion of olanzapine in primary care: An examination of internal industry documents. Social Science and Medicine 69:14-20, 2009
22. Newman M: Bitter pills for drug companies. BMJ 341:c5095, 2010
23. Mental Health: A Report of the Surgeon General. Washington, DC, US Department of Health and Human Services, 1999. Available at www.surgeongeneral. gov/library/mentalhealth/home.html
24. Institute of Medicine, Committee on Quality Health Care in America: Crossing the Quality Chasm: A New Health System for the 21st Century. Washington, DC, National Academies Press, 2001
25. Corrigan PW, Steiner L, McCracken SG, et al: Strategies for disseminating evidencebased practices to staff who treat people with serious mental illness. Psychiatric Services 52:1598-1606, 2001
26. Goldman HH, Ganju V, Drake RE, et al: Policy implications for implementing evidence-based practices. Psychiatric Services 52:1591-1597, 2001
27. Achieving the Promise: Transforming Mental Health Care in America. Pub no SMA-03-3832. Rockville, Md, Department of Health and Human Services, President's New Freedom Commission on Mental Health, 2003
28. Panzano PC, Roth D: The decision to adopt evidence-based and other innovative mental health practices: risky business? Psychiatric Services 57:1153-1161, 2006
29. Valenstein M, McCarthy JF, Ignacio RV, et al: Patient-and facility-level factors associated with diffusion of a new antipsychotic in the VA health system. Psychiatric Services 57:70-76, 2006
30. Penfold RB, Kelleher KJ: Use of surveillance data in developing geographic dissemination strategies: A study of the diffusion of olanzapine to Michigan children insured by Medicaid. Clinical Therapeutics 29:357-370, 2007
31. DeLeon A, Patel NC, Crismon ML: Aripiprazole: A comprehensive review of its pharmacology, clinical efficacy, and tolerability. Clinical Therapeutics 26:649-666, 2004
32. Bhattacharjee J, El-Sayeh HG: Aripiprazole versus typical antipsychotic drugs for schizophrenia. Cochrane Database of Systematic Reviews 3:CD006617, 2008
33. Masand PS, Arora M, Schwartz TL, et al: Prescribing conventional antipsychotics at two Veterans Administration hospitals: Are there geographical differences? CNS Spectrums 6:894-896, 2001
34. Pugh MJ, Anderson J, Pogach LM, et al: Differential adoption of pharmacotherapy recommendations for type 2 diabetes by generalists and specialists. Medical Care Research and Review 60:178-200, 2003
35. Zhang Y, Baicker K, Newhouse JP: Geographic variation in the quality of prescribing. New England Journal of Medicine 363:1985-1988, 2010
36. Wetmore JB, Mahnken JD, Mukhopadhyay P, et al: Geographic variation in cardioprotective antihypertensive medication usage in dialysis patients. American Journal of Kidney Diseases 58:73-83, 2011
37. Harpaz-Rotem I, Rosenheck RA: Tracing the flow of knowledge: geographic variability in the diffusion of prazosin use for the treatment of posttraumatic stress disorder nationally in the Department of Veterans Affairs. Archives of General Psychiatry 66:417-421, 2009
38. Burt RS: Social contagion and innovation: cohesion versus structural equivalence. American Journal of Sociology 92:1287-1335, 1987
39. Valente TW: Social network thresholds in the diffusion of innovations. Social Networks 18:69-89, 1996
40. van den Bulte C, Lilien GL: Medical innovation revisited: social contagion versus marketing effort. American Journal of Sociology 106:1409-1435, 2001
41. van den Bulte C, Stremersch S: Social contagion and income heterogeneity in new product diffusion: A meta-analytic test. Marketing Science 23:530-544, 2004
42. Young HP: Innovation diffusion in heterogeneous populations: contagion, social influence, and social learning. American Economic Review 99:1899-1924, 2009
43. Iyengar R, van den Bulte C, Valente TW: Opinion leadership and social contagion in new product diffusion. Marketing Science 30:195-212, 2011
44. Dearing JW: Evolution of diffusion and dissemination theory. Journal of Public Health Management and Practice 14: 99-108, 2008
45. Dearing JW: Applying diffusion of innovation theory to intervention development. Research on Social Work Practice 19:503-518, 2009
46. Kilbourne AM, Goodrich D, Miklowitz DJ, et al: Characteristics of patients with bipolar disorder managed in VA primary care or specialty mental health care settings. Psychiatric Services 61:500-507, 2010
47. Kilbourne AM, Pirraglia PA, Lai Z, et al: Quality of general medical care among patients with serious mental illness: does colocation of services matter? Psychiatric Services 62:922-928, 2011
48. Keck PE, Jr, Marcus R, Tourkodimitris S, et al: A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. American Journal of Psychiatry 160: 1651-1658, 2003
49. Lyseng-Williamson KA, Perry CM: Aripiprazole: in acute mania associated with bipolar I disorder. CNS Drugs 18:367-378, 2004
50. Supplemental New Drug Application Approval Letter re: NDA 21-436/S-005. Washington, DC, Food and Drug Administration, March 1, 2005. Available at www.accessdata.fda.gov/drugsatfda-docs/appletter/2005/21436s005,008, 21713s003ltr.pdf
51. Supplemental New Drug Application Approval Letter re: NDA 21-436/S-002. Washington, DC, Food and Drug Administration, Sept 29, 2004. Available at www.accessdata.fda.gov/drugsatfda-docs/appletter/2004/21436s002ltr.pdf
52. Kilbourne AM, Greenwald DE, Hermann RC, et al: Financial incentives and accountability for integrated medical care in Department of Veterans Affairs mental health programs. Psychiatric Services 61: 38-44, 2010
53. Mohr DC, Burgess JFJ, Jr: Job characteristics and job satisfaction among physicians involved with research in the Veterans Health Administration. Academic Medicine 86:938-945, 2011
54. Sernyak M, Rosenheck R: Experience of VA psychiatrists with pharmaceutical detailing of antipsychotic medications. Psychiatric Services 58:1292-1296, 2007
55. Hamilton RJ, Kahwati LC, Kinsinger LS: Knowledge and use of finasteride for the prevention of prostate cancer. Cancer Epidemiology, Biomarkers and Prevention 19: 2164-2171, 2010
56. Hosmer DW, Lemeshow S: Applied Logistic Regression, 2nd ed. New York, Wiley, 2000
57. Greenhalgh T, Robert G, Macfarlane F, et al: Diffusion of innovations in service organizations: systematic review and recommendations. Milbank Quarterly 82: 581-629, 2004